Aquestive Therapeutics, Inc. (AQST) stock
AQSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.70−0.06 (-1.60%)
Close on Nov 17, 2026Market cap $464.39MP/E –Yield –
Aquestive Therapeutics cash
Cash and short-term investments held at the end of each period.
Aquestive Therapeutics's cash was $98.49M at Jun 30, 2026. For fiscal 2025 it was $121.17M, up 69.4% from the year before. The highest annual figure on record is $121.17M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $121.17M | +69.4% |
| FY2024 | Dec 31, 2024 | $71.55M | +199.7% |
| FY2023 | Dec 31, 2023 | $23.87M | -12.5% |
| FY2022 | Dec 31, 2022 | $27.27M | -2.7% |
| FY2021 | Dec 31, 2021 | $28.02M | -11.9% |
| FY2020 | Dec 31, 2020 | $31.81M | -35.5% |
| FY2019 | Dec 31, 2019 | $49.33M | -18.6% |
| FY2018 | Dec 31, 2018 | $60.60M | +248.7% |
| FY2017 | Dec 31, 2017 | $17.38M | +88.7% |
| FY2016 | Dec 31, 2016 | $9.21M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $98.49M | +62.7% |
| Q1 FY2026 | Mar 31, 2026 | $110.73M | +61.3% |
| Q4 FY2025 | Dec 31, 2025 | $121.17M | +69.4% |
| Q3 FY2025 | Sep 30, 2025 | $129.06M | +65.7% |
| Q2 FY2025 | Jun 30, 2025 | $60.54M | -32.6% |
| Q1 FY2025 | Mar 31, 2025 | $68.66M | -27.9% |
| Q4 FY2024 | Dec 31, 2024 | $71.55M | +199.7% |
| Q3 FY2024 | Sep 30, 2024 | $77.89M | +212.6% |
| Q2 FY2024 | Jun 30, 2024 | $89.87M | +300.6% |
| Q1 FY2024 | Mar 31, 2024 | $95.20M | +254.1% |
| Q4 FY2023 | Dec 31, 2023 | $23.87M | -12.5% |
| Q3 FY2023 | Sep 30, 2023 | $24.92M | +33.6% |
| Q2 FY2023 | Jun 30, 2023 | $22.44M | +26.8% |
| Q1 FY2023 | Mar 31, 2023 | $26.88M | +82.4% |
| Q4 FY2022 | Dec 31, 2022 | $27.27M | -2.7% |
| Q3 FY2022 | Sep 30, 2022 | $18.65M | -40.2% |
| Q2 FY2022 | Jun 30, 2022 | $17.70M | -48.3% |
| Q1 FY2022 | Mar 31, 2022 | $14.74M | -46.4% |
| Q4 FY2021 | Dec 31, 2021 | $28.02M | -11.9% |
| Q3 FY2021 | Sep 30, 2021 | $31.16M | +82.6% |
| Q2 FY2021 | Jun 30, 2021 | $34.23M | +34.7% |
| Q1 FY2021 | Mar 31, 2021 | $27.50M | -22.6% |
| Q4 FY2020 | Dec 31, 2020 | $31.81M | -35.5% |
| Q3 FY2020 | Sep 30, 2020 | $17.06M | -18.4% |
| Q2 FY2020 | Jun 30, 2020 | $25.42M | +14.7% |
| Q1 FY2020 | Mar 31, 2020 | $35.52M | -11.1% |
| Q4 FY2019 | Dec 31, 2019 | $49.33M | -18.6% |
| Q3 FY2019 | Sep 30, 2019 | $20.91M | -67.3% |
| Q2 FY2019 | Jun 30, 2019 | $22.17M | +34.4% |
| Q1 FY2019 | Mar 31, 2019 | $39.93M | +129.8% |
| Q4 FY2018 | Dec 31, 2018 | $60.60M | +138.2% |
| Q3 FY2018 | Sep 30, 2018 | $63.98M | +521.8% |
| Q1 FY2018 | Mar 31, 2018 | $16.49M | +79.0% |
| Q4 FY2017 | Dec 31, 2017 | $17.38M | – |
| Q3 FY2017 | Sep 30, 2017 | $25.44M | – |
| Q2 FY2017 | Jun 30, 2017 | $10.29M | – |
| Q4 FY2016 | Dec 31, 2016 | $9.21M | – |
See a number that looks wrong?